Whitepapers

Sep 01, 2016
Sponsored Content
Vaccines are one of the most efficacious health investments in history at preventing widespread infectious diseases and reducing human mortality. However, with more than 450 vaccines in development, only one in 10 will reach the populations that need them. You need one global partner to help transform your vaccine development programs. Learn more at www.quintiles.com/vaccines.
Aug 23, 2016
Pharmaceutical Executive
Pharm Exec talks to Mollie Shields-Uehling, a leading advocate for high-assurance identity trust for cyber-transactions in the biopharmaceutical industry. Read our executive summary covering topics like cyber/technical security; eHealth regulatory compliance; work flow automation, the benefits of eSignature programs, and collaboration around key aspects of drug development like the administration of clinical trials and research partnering.
Jul 22, 2016
Pharmaceutical Executive
Drug pricing is a constant hum in the news, begging the question are drug prices really too high? This white paper aims to parse out the real issues at play in the biopharmaceutical market and examine what dynamics are occurring by using oncology in the United States as a case study.
Jul 19, 2016
Sponsored Content
According to Global Genes, more than 350 million people worldwide suffer from rare diseases. Unfortunately, according to the FDA’s Every Life Foundation, only around 5% of rare diseases have a FDA-approved treatment.Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, has worked on more than 245 rare disease studies in 96 countries since 2010. Here, Laurie Witherwax outlines the patient-centric approach that Quintiles deploys to help pharmaceutical and biotechnology companies get new therapies to patients.
Jun 03, 2016
Pharmaceutical Executive
By leveraging co-pay support programs as front-end patient acquisition tactics, marketers can use them as a means of engaging patients in the brand’s integrated and multifaceted marketing stream
May 31, 2016
Pharmaceutical Executive
Medication adherence is a broadly recognized problem that compromises both clinical and economic outcomes of drug treatments. Medication adherence is also a problem with a solution. The use of what is often called “smart packing,” standard pharmaceutical packages with an embedded microchip to detect opening and closing, can give healthcare providers key information on precisely when each dose was taken—or when it was missed. The ability to identify and quantify both adherence and nonadherence promises to improve clinical outcomes and reduce overall healthcare spending.
Apr 20, 2016
Pharmaceutical Executive
The all-new 2016 Chevrolet Malibu offers exceptional style, safety, and efficiency that will be popular with reps and desirable for fleet managers. Read this whitepaper and infographic that demonstrate the features and technologies that make Chevrolet Malibu a great option for pharma fleets.
Apr 01, 2016
Pharmaceutical Executive
How do you really know if your co-pay program is working? Figuring ROI seems straightforward. But Paul LeVine, Vice President of Analytic Services for TrialCard Market Access Solutions thinks the calculus might require a deeper look than is traditionally given as he explained at the 2nd Annual Coupon and Co-Pay Strategy Summit in Philadelphia in February.
Mar 16, 2016
Sponsored Content
The U.S. has been among the most sought-after pharmaceutical markets in the world for decades. But accessing this enormous market is not easy. Not only must entrants gain marketing approval from the Food and Drug Administration, they must also ensure access to patients by gaining prescriber and payer acceptance. Meeting the combined challenges of marketing approval, payer acceptance, assured reimbursement and access to patients is the result of a studied and deliberate approach to product development and launch. This studied approach is particularly important in rare disease product categories with low numbers of patients, high development costs and managed care plans focused on controlling spend.
Mar 10, 2016
Pharmaceutical Executive
Darryl Williams, Head of Global MDM and Platform Solutions, Health Care, for LexisNexis Risk Solutions discussed the impact of Big Data in the Life Sciences with Fierce Markets on December 8, 2015. This white paper is an expansion of the discussion exploring how and why big data will have a big impact on Life Sciences in 2016 and beyond.
native1_300x100
lorem ipsum